Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Cell Immunol. 2021 May;363:104314. doi: 10.1016/j.cellimm.2021.104314. Epub 2021 Feb 23.
T cell-based adoptive cell transfer therapy is now clinically used to fight cancer with CD19-targeting chimeric antigen receptor T cells. The use of other T cell-based immunotherapies relying on antigen-specific T cells, genetically modified or not, is expanding in various neoplastic diseases. T cell manufacturing has evolved through sophisticated processes to produce T cells with improved therapeutic potential. Clinical-grade manufacturing processes associated with these therapies must meet pharmaceutical requirements and therefore be standardized. Here, we focus on the use of cytokines to expand minimally differentiated T cells, as well as their standardization and harmonization in research and clinical settings.
基于 T 细胞的过继细胞转移疗法目前已在临床上用于使用针对 CD19 的嵌合抗原受体 T 细胞来对抗癌症。在各种肿瘤疾病中，基于抗原特异性 T 细胞（无论是否经过基因修饰）的其他 T 细胞免疫疗法的应用正在不断扩大。T 细胞的制造已经通过复杂的工艺得到了发展，以生产具有改善治疗潜力的 T 细胞。与这些疗法相关的临床级制造工艺必须符合药物要求，因此需要标准化。在这里，我们重点介绍使用细胞因子来扩增低度分化的 T 细胞，以及在研究和临床环境中对其进行标准化和协调。
